TEMPEST THERAPEUTICS, INC.

Consensus Tempest Therapeutics, Inc.

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-24 EDT			5-day change	1st Jan Change
1.100 ^USD	+5.77%		-2.65%	-61.67%

08-13	Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-22	Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement	CI

Evolution of the Average Target: Tempest Therapeutics, Inc.

Evolution of the Target Price: Tempest Therapeutics, Inc.

Changes in Analyst Recommendations: Tempest Therapeutics, Inc.

cf4ce5e78ad765e175d8fa9.9q8u4ki-_rLdLiMVJH3-ImMx_Zb8z095LfLfYCo9T0E.vJ9ksyHhsYCSGGRSYj7HVlBpp9Cmux0XQ6uYAnUKdni3l16uO9fL175Deg~185e75528e82b4ec1b152d94fc40140e

Analysts' recommendations: Tempest Therapeutics, Inc.

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
25-04-10	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
24-03-14	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
23-10-11	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23-03-23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT
22-09-15	Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	MT
22-05-13	HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	MT
22-04-28	Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	MT
21-10-21	Tempest Therapeutics : William Blair Initiates Tempest Therapeutics at Outperform Rating	MT
21-07-13	Tempest Therapeutics : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	MT
21-07-06	Tempest Therapeutics : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPEST THERAPEUTICS, INC.			-	-	+957.69%
	LONZA GROUP AG					+15.02%
	REVOLUTION MEDICINES, INC.					+6.58%
	IQVIA HOLDINGS INC.					+5.91%
	BEONE MEDICINES AG					+15.63%
	CELLTRION, INC.					+38.34%
	MEDPACE HOLDINGS, INC.					-6.27%
	ASCENDIS PHARMA A/S					+23.52%
	EUROFINS SCIENTIFIC SE					-0.43%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-4.81%
	Average					+105.12%
	Weighted average by Cap.					+12.42%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.100USD

Average target price

11.00USD

Spread / Average Target

+900.00%

High Price Target

11.00USD

Spread / Highest target

+900.00%

Low Price Target

11.00USD

Spread / Lowest Target

+900.00%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

HC Wainwright
Scotiabank
Piper Sandler
Ladenburg Thalmann
William Blair & Co.

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.100USD

Average target price

11.00USD

Spread / Average Target

+900.00%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
TPST Stock
Consensus Tempest Therapeutics, Inc.

The best tools reserved for subscribers to boost the performance of your investments!